GlassScriptPhysician profile
Wanda L Brown
NPI 1083071237
$4,243.66
in general payments reported to CMS, 2019-2025
24 companies · $20.35 in 2025
The $20.35 reported for 2025 was less than what a typical Women'S Health (Nurse Practitioner) provider received nationally (typical 2025 total: $123).
See the full distribution for Women's Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $719 · 2022: $1,304 · 2023: $1,634 · 2024: $566 · 2025: $20.35.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,220.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,220.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $513.31 | 2021-2023 | |
| Novo Nordisk INC | $374.99 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $370.68 | 2022-2024 | Relistor, Trulance |
| Glaxosmithkline, LLC. | $363.37 | 2021-2023 | Arexvy |
| Astrazeneca Pharmaceuticals LP | $287.61 | 2022-2023 | Breztri |
| Teva Pharmaceuticals USA, INC. | $260.00 | 2022-2024 | Austedo Xr |
| Boehringer Ingelheim Pharmaceuticals, INC. | $249.97 | 2022-2024 | Jardiance |
| Mayne Pharma Commercial LLC | $210.14 | 2023 | |
| Artivion, INC. | $166.67 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $125.00 | 2022 | |
| Paratek Pharmaceuticals, INC. | $125.00 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $124.93 | 2021 | |
| Medtronic, INC. | $122.82 | 2023 | Interstim |
| Idorsia Pharmaceuticals US INC | $120.78 | 2023 | Quviviq |
| Amgen INC. | $120.00 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $116.78 | 2023 | Gvoke Hypopen |
| Otsuka America Pharmaceutical, INC. | $109.80 | 2023 | Rexulti |
| Phathom Pharmaceuticals, INC. | $108.51 | 2024 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $99.38 | 2023 | |
| Sk Life Science, INC. | $83.33 | 2022 | |
| Lilly USA, LLC | $78.89 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $75.00 | 2023 | Lifevest |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $20.35 | 2025 | Caplyta |
| Boston Scientific Corporation | $16.35 | 2024 | Rezum Generator |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wanda Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.